Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice

European Journal of Cancer Part A

Volumn 33, Issue 7, 1997, Pages 1108-1113

  Van Den Berg, C L ^a   Cox, G N ^b   Stroh, C A ^b   Hilsenbeck, S G ^a   Weng, C N ^a   McDermott, M J ^b   Pratt, D ^b   Osborne, C K ^a   Coronado Heinsohn, E B ^a   Yee, D ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b AMGEN INC   (United States)

Author keywords

Human breast cancer cell lines; Insulin like growth factor; Insulin like growth factor binding protein

Indexed keywords

MACROGOL; SOMATOMEDIN BINDING PROTEIN 1;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HALF LIFE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ASCITES; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MICE; MICE, NUDE; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030872966     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00071-3     Document Type: Article

References (30)

1. LeRoith D, Baserga R, Helman L, Roberts CT. Insulin-like growth factors and cancer. Ann Intern Med 1995, 122, 54-59.
2. Baserga R. Oncogenes and the strategy of growth factors. Cell 1994, 79, 927-940.
3. Nakao-Hayashi J, Ito H, Kanayasu T, Morita I, Murato S. Stimulatory effects of insulin and insulin-like growth factor on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992, 92, 141-148.
4. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor I as an angiogenic agent. Ann NY Acad Sci 1993, 692, 230-242.
5. Sell C, Dumenil C, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994, 14, 3604-3612.
6. Resnicoff M, Abraham D, Yutanawiboonchai W, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995, 55, 2463-2469.
7. Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 1995, 55, 2448-2454.
8. Ellis MJC, Leav BA, Yang ZJ, et al. Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells. Mol Endocrinol 1996, 10, 286-297.
9. Yee D, Cullen KJ, Paik S. Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 1988, 48, 6691-6696.
10. Yee D, Paik S, Lebovic GS, et al. Analysis of insulin-like growth factor gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989, 3, 509-517.
11. Artega CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against type I somatomedin receptor. Cancer Res 1989, 49, 6237-6241.
12. Brünner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME, Cullen KJ. Effect of endocrine therapy on growth T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer 1993, 29A, 562-569.
13. Clemmons DR. IGF binding proteins and their functions. Mol Reprod Devel 1993, 35, 368-375.
14. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 1990, 127, 2679-2686.
15. Pekonen F, Nyman T, Ilvesmaki V, Partanen S. Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res 1992, 52, 5204-5207.
16. Owens PC, Gill PG, De Young NJ, Weger MA, Knowles SE, Moyse KJ. Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cells. Biochem Biophys Res Commun 1993, 193, 467-473.
17. Yee D, Shamasaki S, Powell DR, McGuire WLJ, Jackson JG. The patterns of insulin-like growth factor binding protein (IGFBP) expression in breast cancer cells suggest a strategy for their use as IGF inhibitors. Breast Cancer Treat Res 1991, 19, 211.
18. Busby WHJ, Klapper DG, Clemmons DR. Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid, isolation of two forms with different biological actions. J Biol Chem 1988, 263, 14203-14210.
19. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Recombinant insulin-like growth factor protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 1993, 157, 229-236.
20. Yee D, Van Den Berg C, Kozelsky TW, Kuhn JG, Cox GN. Pharmacokinetic profile of recombinant human insulin-like growth factor binding protein-1 in athymic mice. Biomed Pharmacother 1996, 50, 154-157.
21. Hossenlopp P, Seurin D, Seovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western blotting; use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986, 154, 138-143.
22. Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Treat Res 1994, 31, 1-11.
23. DeMellow JSM, Baxter RC. Growth hormone dependent insulin-like growth factor binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 1988, 156, 199-204.
24. Chen JC, Shao ZM, Sheikh MS, et al. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I) mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 1994, 158, 69-78.
25. Camacho-Hubner C, McCusker RH, Clemmons DR. Secretion and biological actions of insulin-like growth factor binding proteins in two human tumour-derived cell lines in vitro. J Cell Physiol 1991, 148, 281-289.
26. Castantino A, Milazzo F, Giorgino P, et al. Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity. Mol Endocrinol 1993, 7, 1667-1676.
27. Rutanen E-M, Pekonen F, Makinen T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptor in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J Clin Endocrinol Metab 1988, 66, 173-180.
28. Sahlin L, Norstedt G, Ericksson H. Estrogen regulation of the estrogen receptor and insulin-like growth factor-I in the rat uterus: a potential role of coupling between effects of estrogen and IGF. Steroids 1994, 59, 421-430.
29. Giudice LC. Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil Steril 1994, 61, 1-17.
30. Artega CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989, 84, 1418-1423.